grant
Multiomic strategies to assess HIV reservoir persistence
Organization UNIVERSITY OF PENNSYLVANIALocation PHILADELPHIA, UNITED STATESPosted 1 Apr 2023Deadline 31 Mar 2028
NIHUS FederalResearch GrantFY2026AIDS VirusATACATAC sequencingATAC-seqATACseqAcquired Immune Deficiency Syndrome VirusAcquired Immunodeficiency Syndrome VirusAddressAfter CareAfter-TreatmentAftercareAnatomic SitesAnatomic structuresAnatomyAnti-HIV PositivityApoptosisApoptosis PathwayAssayAssay for Transposase-Accessible Chromatin using sequencingBasal Transcription FactorBasal transcription factor genesBindingBioassayBiological AssayBloodBlood Reticuloendothelial SystemBlood SampleBlood specimenCAR T cellsCAR modified T cellsCAR-TCAR-TsCD4 CellsCD4 Positive T LymphocytesCD4 T cellsCD4 helper T cellCD4 lymphocyteCD4+ T-LymphocyteCD4-Positive LymphocytesCell BodyCell DeathCell Surface AntigensCell SurvivalCell ViabilityCell surfaceCellsCharacteristicsClinical TrialsCombination immunotherapyDNADataDeoxyribonucleic AcidDetectionDevelopmentEpigeneticEpigenetic ChangeEpigenetic MechanismEpigenetic ProcessFailureGene TranscriptionGeneral Transcription Factor GeneGeneral Transcription FactorsGenesGeneticGenetic TranscriptionGoalsHIVHIV PositiveHIV PositivityHIV SeroconversionHIV SeropositivityHIV antibody positiveHIV cureHIV functional cureHIV individualsHIV infected individualsHIV infected personsHIV peopleHIV positive individualsHIV positive peopleHIV resistanceHIV resistantHIV+HIV-1 cureHIV-1 functional cureHIV/AIDS cureHTLV-III SeroconversionHTLV-III SeropositivityHeterogeneityHumanHuman Immunodeficiency VirusesIFNImmune mediated therapyImmunological Surface MarkersImmunologically Directed TherapyImmunotherapeutic agentImmunotherapyIn VitroIndividualInfectionInterferonsInterruptionLAV-HTLV-IIILPTNLymphadenopathy-Associated VirusLymphatic TissueLymphoid TissueModalityModelingModern ManMolecular InteractionNon-Polyadenylated RNAOutcomePLWHPWHPredispositionProgrammed Cell DeathPropertyProteinsProvirus IntegrationProvirusesRNARNA ExpressionRNA Gene ProductsResistanceRestRibonucleic AcidSCM-1SCM-1aSCM1SCYC1SamplingSurfaceSurface AntigensSusceptibilitySystemT cells for CART4 CellsT4 LymphocytesTestingTimeTranscriptTranscriptionTranscription Factor Proto-OncogeneTranscription factor genesTransposaseViralViral reservoirVirus reservoirVirus-HIVXCL1XCL1 geneantiretroviral therapyantiretroviral treatmentassay for transposase accessible chromatin followed by sequencingassay for transposase accessible chromatin seqassay for transposase accessible chromatin sequencingassay for transposase-accessible chromatin with sequencingchimeric antigen T cell receptorchimeric antigen receptor (CAR) T cellschimeric antigen receptor Tchimeric antigen receptor T cellschimeric antigen receptor fusion protein T-cellschimeric antigen receptor modified T cellscombinatorial immunotherapydevelopmentaldual immunotherapyepigeneticallyepigenomeglobal gene expressionglobal transcription profilehuman immunodeficiency virus cureimmune drugsimmune therapeutic approachimmune therapeutic interventionsimmune therapeutic regimensimmune therapeutic strategyimmune therapyimmune-based therapeuticsimmune-based therapiesimmune-based treatmentsimmuno therapyimmunologic therapeuticsimmunotherapeuticsimmunotherapy agentin vivoindividuals infected with HIVindividuals with HIVindividuals with human immunodeficiency virusinhibitorinsightintegration sitelatent HIV reservoirlatent HIV-1 reservoirlatent HIV1 reservoirmulti-modalitymultimodalitymultiomicsmultiple omicsnecrocytosisnovelpanomicspeople infected with HIVpeople infected with human immunodeficiency viruspeople living with HIVpeople with HIVpeople with human immunodeficiency virusperipheral bloodphenotypic biomarkerphenotypic markerpost treatmentresistance mechanismresistantresistant mechanismscRNA sequencingscRNA-seqsingle cell RNA-seqsingle cell RNAseqsingle cell expression profilingsingle cell transcriptomic profilingsingle-cell RNA sequencingsuccesstranscription factortranscriptometranscriptomics
Get Agency plan to apply$29.99/mo · 7-day free trial · pipeline · alerts
or
— or —Get email alerts for similar roles
Description preview
Persistence of the latent HIV reservoir in people living with HIV (PLWH) remains the critical barrier to an HIV
cure. Numerous reservoir reduction and control studies have met with only limited success due to our profound
lack of understanding of the cellular mechanisms that allow the HIV reservoir to persist during antiretroviral
therapy (ART).…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click